ADVA
2.11.2021 09:02:06 CET | Business Wire | Press release
ADVA (FSE: ADV) today introduced its OSA 5400 SyncModule™ embedded timing solution, enabling technology suppliers to easily integrate precise synchronization into their hardware. The M.2 form factor module offers equipment vendors a way to simply and cost-effectively add crucial timing capabilities with key functionality into their switches, routers, open compute servers and other IT devices. Featuring GNSS, PTP and NTP engines as well as comprehensive PTP and GNSS monitoring and assurance functionality, the OSA 5400 SyncModule™ empowers third-party companies to leverage the unique expertise of ADVA’s Oscilloquartz synchronization specialists. The solution will provide a major boost to suppliers of mobile infrastructure and white box vendors. It will be key for enabling assured sub-microsecond timing in public and private networks as well as critical infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005094/en/
“Our OSA 5400 SyncModule™ brings something completely new and very valuable to the market. For the first time, third-party technology manufacturers will be able to embed the most advanced synchronization capabilities into their designs and easily control them with our Ensemble Sync Director or their own management system,” said Gil Biran, general manager, Oscilloquartz, ADVA. “With our OSA 5400 SyncModule™ , we’re extending the disaggregated approach to building networks into the area of synchronization. The integrated solution gives vendors the ability to instantly inject the most advanced, highly accurate and fully assured timing into their hardware platforms. As our solution utilizes the widely applied, standardized M.2 interface, integration is simple. It can also easily be added to existing designs.”
The trend towards network disaggregation is accelerating innovation and expanding the market for customers. This does, however, create a challenge for technology suppliers when it comes to synchronization. Now, the OSA 5400 SyncModule™ is filling that gap. The low-power M.2 module gives vendors of emerging technologies, such as open RAN and next-generation data center hardware, the ability to quickly harness the benefits of an integrated GNSS receiver, PTP, NTP and assurance engines, as well as full sync management functionality. Featuring multiple interface options for easy integration, the OSA 5400 SyncModule™ comes with an open API for simple configuration. It can also be managed by ADVA’s proven Ensemble Sync Director management system for complete control of the timing infrastructure.
“Cost-effective and hassle-free, our new embedded timing solution brings highly precise and assured synchronization to a whole new market. For companies who are suppliers of 5G RAN hardware or open compute servers, our OSA 5400 SyncModule™ offers major value,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Vendors like those, who are not necessarily experts in network timing, now have the opportunity to instantly pour all of our synchronization know-how into their solutions. And that enables customers to choose the ideal components for their specific needs complete with the best available timing.”
Watch this video to learn more about the OSA 5400 SyncModule™ : https://youtu.be/iPUl_n0dvJU .
Further information is also available in these slides: https://adva.li/osa-5400-syncmodule-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005094/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
